• Something wrong with this record ?

Antimicrobial peptide isolated from Bacillus amyloliquefaciens K14 revitalizes its use in combinatorial drug therapy

S. Regmi, YH. Choi, YS. Choi, MR. Kim, JC. Yoo,

. 2017 ; 62 (2) : 127-138. [pub] 20161027

Language English Country United States

Document type Journal Article

The present study was performed to evaluate the antibacterial activities of an antimicrobial peptide (CSpK14) and the synergies thereof with β-lactams against vancomycin-resistant Staphylococcus aureus (VRSA) and Enterococci (VRE). Our strain was isolated from fermented food (kimchi), which is 99.79 % homologous with Bacillus amyloliquefaciens subsp. plantarum FZB42(T). CSpK14 was purified to homogeneity by diammonium sulfate precipitation, concentration, dialysis, and followed by two-stage chromatographic separation, i.e., Sepharose Cl-6B and Sephadex G-25 chromatography, and had a molar mass of ~4.6 kDa via Tricine SDS-PAGE and in situ examination. It was stable at pH 6.0-11.5 and temperature up to 80 °C. In addition, it was also stable with various metal ions, solvents, and proteases. The N-terminal amino acid sequence was H-Y-D-P-G-D-D-S-G-N-T-G and did not show any significant homology with reported peptides. However, it shows some degrees of identity with alpha-2-macroglobulin and ligand-gated channel protein from different microorganisms. CSpK14 significantly reduced the minimum inhibitory concentrations (MICs) of β-lactams and had no effect on non-β-lactams against VRSA and VRE. MICs of CSpK14/oxacillin and CSpK14/ampicillin were reduced by 8- to 64-fold and 2- to 16-fold, respectively. The time killing assay between CSpK14/oxacillin (2.29-2.37 Δlog10CFU/mL at 24 h) and CSpK14/ampicillin (2.30-2.38 Δlog10CFU/mL at 24 h) being >2-fold and fractional inhibitory concentration index ˂0.5 revealed synergy. Furthermore, the biofilms formed by VRSA and VRE were reduced completely. CSpK14 was simple to purify, had low molecular mass, was stable over a wide pH range or tested chemicals, had broad inhibitory spectrum, and possessed potent synergistic antimicrobial-antibiofilm properties. CSpK14 synergistically enhanced the efficacy of β-lactams and is therefore suitable for combination therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17010574
003      
CZ-PrNML
005      
20170321103330.0
007      
ta
008      
170321s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12223-016-0479-2 $2 doi
035    __
$a (PubMed)27787755
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Regmi, Sudip $u Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, South Korea.
245    10
$a Antimicrobial peptide isolated from Bacillus amyloliquefaciens K14 revitalizes its use in combinatorial drug therapy / $c S. Regmi, YH. Choi, YS. Choi, MR. Kim, JC. Yoo,
520    9_
$a The present study was performed to evaluate the antibacterial activities of an antimicrobial peptide (CSpK14) and the synergies thereof with β-lactams against vancomycin-resistant Staphylococcus aureus (VRSA) and Enterococci (VRE). Our strain was isolated from fermented food (kimchi), which is 99.79 % homologous with Bacillus amyloliquefaciens subsp. plantarum FZB42(T). CSpK14 was purified to homogeneity by diammonium sulfate precipitation, concentration, dialysis, and followed by two-stage chromatographic separation, i.e., Sepharose Cl-6B and Sephadex G-25 chromatography, and had a molar mass of ~4.6 kDa via Tricine SDS-PAGE and in situ examination. It was stable at pH 6.0-11.5 and temperature up to 80 °C. In addition, it was also stable with various metal ions, solvents, and proteases. The N-terminal amino acid sequence was H-Y-D-P-G-D-D-S-G-N-T-G and did not show any significant homology with reported peptides. However, it shows some degrees of identity with alpha-2-macroglobulin and ligand-gated channel protein from different microorganisms. CSpK14 significantly reduced the minimum inhibitory concentrations (MICs) of β-lactams and had no effect on non-β-lactams against VRSA and VRE. MICs of CSpK14/oxacillin and CSpK14/ampicillin were reduced by 8- to 64-fold and 2- to 16-fold, respectively. The time killing assay between CSpK14/oxacillin (2.29-2.37 Δlog10CFU/mL at 24 h) and CSpK14/ampicillin (2.30-2.38 Δlog10CFU/mL at 24 h) being >2-fold and fractional inhibitory concentration index ˂0.5 revealed synergy. Furthermore, the biofilms formed by VRSA and VRE were reduced completely. CSpK14 was simple to purify, had low molecular mass, was stable over a wide pH range or tested chemicals, had broad inhibitory spectrum, and possessed potent synergistic antimicrobial-antibiofilm properties. CSpK14 synergistically enhanced the efficacy of β-lactams and is therefore suitable for combination therapy.
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a ampicilin $x farmakologie $7 D000667
650    _2
$a antibakteriální látky $x biosyntéza $x izolace a purifikace $x farmakologie $7 D000900
650    _2
$a kationické antimikrobiální peptidy $x biosyntéza $x izolace a purifikace $x farmakologie $7 D023181
650    _2
$a Bacillus amyloliquefaciens $x klasifikace $x imunologie $x metabolismus $7 D000069977
650    _2
$a biofilmy $x účinky léků $x růst a vývoj $7 D018441
650    _2
$a chromatografie iontoměničová $7 D002852
650    _2
$a synergismus léků $7 D004357
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a oxacilin $x farmakologie $7 D010068
650    _2
$a fylogeneze $7 D010802
650    _2
$a stabilita proteinů $7 D055550
650    _2
$a Staphylococcus aureus $x účinky léků $x růst a vývoj $7 D013211
650    _2
$a rezistence na vankomycin $x účinky léků $7 D020713
650    _2
$a enterokoky rezistentní vůči vankomycinu $x účinky léků $x růst a vývoj $7 D065507
655    _2
$a časopisecké články $7 D016428
700    1_
$a Choi, Yun Hee $u Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, South Korea.
700    1_
$a Choi, Yoon Seok $u Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, South Korea.
700    1_
$a Kim, Mi Ri $u Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, South Korea.
700    1_
$a Yoo, Jin Cheol $u Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, South Korea. jcyu@chosun.ac.kr.
773    0_
$w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 62, č. 2 (2017), s. 127-138
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27787755 $y Pubmed
910    __
$a ABA008 $b online $c sign $y a $z 0
990    __
$a 20170321 $b ABA008
991    __
$a 20170321103601 $b ABA008
999    __
$a ok $b bmc $g 1195197 $s 971290
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 62 $c 2 $d 127-138 $e 20161027 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
LZP    __
$a Pubmed-20170321

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...